Get started

Coronavirusstocks

Regeneron's Covid Treatment First Drug Authorized By FDAMy last chart: November 22, 2020: Regeneron's Coronavirus Treatment Becomes First Antibody Cocktail to Earn Emergency Use Authorization from FDA (The Motley Fool). Regeneron Covid Drug Gets Emergency OK. Antibody drug cocktail casirivimab and imdevimab are allowed for use by people over age 12 with mild or moderate Covid-19. (the street). If you are interested to test some amazing BUY and SELL INDICATORS, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:REGNLong
by TopgOptions
$PFE Missed Our Previous Entry? Now Is Your 2nd Chance To Get InThis is an update for an ongoing $PFE position announced in an earlier post on October 2nd titled "$PFE Expect A Move Towards $41.94". Technical Analysis Currently, $PFE is still respecting the Ascending Triangle chart pattern, where after touching the slope of higher lows at around $35.50 to $36.00, it has flown past our optimal entry level of $36.36 to $36.46 and hit a 1-month high of $38.84 on 20th October 2020. It has since retraced from the highs and closed at $37.49 with a pre-market trading value of $37.66 on 21st October 2020 as of the time that I am writing this post. New Finding 1: I have included a new Slope of Lower Highs based on the Weekly Timeframe as seen in the chart. For those who are baffled as to why there was such a huge rejection after hitting $38.84, this is your answer. If we go back to the 4H chart, we can see that after momentarily breaking the Slope of Lower Highs, there was a huge rejection within the same candle and subsequently closing just below the Slope of Lower Highs. Thus, the rejection was purely a result of a technical move, and not a fundamental problem with the company. In fact, I view this rejection as a very positive bullish indicator because firstly, price is respecting our Ascending Triangle and Symmetrical Triangle very well, which further strengthens our Bullish Bias towards $PFE; and secondly, if $PFE were to continue bulling without the retracement we saw yesterday, it would have brought $PFE's price too high, too fast, creating a 4 Hour Regular Bearish Divergence and false Symmetrical Triangle Breakout. These would have weakened our Bullish Bias towards $PFE, at least from a technical perspective. New Finding 2: Fundamentally, $PFE is still in a very strong position in terms of where it is right now with its COVID-19 vaccine development as well as its first-mover vaccine advantage compared to other companies. We see Pfizer entering into COVID-19 vaccine deals with countries such as New Zealand and Mexico, where they each agreed to acquire 1.5 million and 15.5 million to 34.4 million doses respectively. This is great for Pfizer once their vaccine is approved and produced successfully. We also see 2 high-profile late-stage clinical trial - Eli Lilly's and Johnson & Johnson's test of COVID-19 vaccine coming to a pause due to possible safety concerns, which further strengthens Pfizer's position as a first-mover. New Finding 3: However, I would say that the biggest news that came under my radar would be Pfizer's CEO pushing back COVID-19 vaccine submission to November due to stricter FDA guidelines requiring companies to provide two months' worth of safety data on half of the trial participants following the final dose of any investigational COVID-19 vaccine. I would say that this is one of the best things that the FDA could have ever done for Pfizer because back when Pfizer previously said that it would seek approval by October, there were a lot of distrust, uncertainties, and safety concerns towards a vaccine that was approved and produced so quickly. This could have potentially caused a weaker-than-expected bullish move even if Pfizer managed to get its vaccine approved and produced. However, with a stricter FDA guideline, if Pfizer is still able to get its vaccine approved and produced first in the market, consumers will be more likely and willing to accept usage of their vaccines, leading to a positive bullish catalyst for $PFE. Entries, Price Targets, Stop Losses There are no changes to our price targets and stop losses, so I will not repeat in this post. If you are interested to see what they are in detail, you can refer to my previous post, I have linked it down below in the 'Related Ideas' section. What I want to focus on is the entry. I believe that this pullback has presented itself as a solid price to add a position or even enter a new position if you have missed our previous entry. So, if you would like to enter into $PFE, this is your chance before it breaks the Symmetrical Triangle towards the upside, and subsequently, break the Ascending Triangle. In general, buying in the lower half area of the remaining Symmetrical Triangle would be a great entry. Disclaimer I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor. All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment, or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies. I will not and cannot be held liable for any actions you take as a result of anything you read here. Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise. If this post has helped you out in making your investment/trading decision, give it a huge thumbs up, and follow for more updates regarding this ticker symbol!
NYSE:PFELong
by UnknownUnicorn6361804
NVAX STOCKS DUMPED, DOWNTREND CONTINUESEarlier this year there was the question : How do you invest in Coronavirus vaccine stocks? Now, we have the answer : YOU DONT. Chart looking bleak, and the support lines are weak. This could be due to a few reasons: - Lack of MAINSTREAM updates - NVAX actually has no other vaccines - Market volatility due to covid and elections - Investors are seeking less riskier gains and getting out of stocks that do not look promising Other than the above, we have seen strange behavior with stocks of companies in the race. A few examples: PFE Pfizer stock not responding to numerous huge injections from government REGN Regeneron stocks hardly responding to Trump pimp GILD Gilead even FALLING after being the first company world wide to receive FDA approval for remdesivir as a treatment. AZN Astrazeneca in conjunction with Oxford has a trail candidate dead but stocks remain largely unaffected I think NVAX has potential in the long run, long term I remain bullish for the company fundamentally, but not for an investment choice right now. In fact I'd say that no vaccine stock is a good investment right now. The way the market reacts to news is too unpredictable and the future remains uncertain. Hit like if you found this insightful and helpful Thanks, Ev
NASDAQ:NVAX
by BlockTechEv
1
NRG ENERGY BEARISHNRG is my renewable energy choice. It has great potential for growth and is currently undervalued by at least 27% according to Yahoo finance. At this moment the stock market is seeing a huge drawback and as we near the election, markets are becoming more volatile. Currently, NRG might correct to $30 over the next few days. If $30 does not hold, next stop is $28. Watch the DMI and MACD for trend reversal and buy the dip as low as you can. NRG with regards to the election, my prediction : a Biden win surges NRG upward a Trump win will correct NRG to levels below $28. BUT, it will climb again after the election. Hit like if you found this helpful. Thanks, Ev
NYSE:NRG
by BlockTechEv
1
NVDA CORRECTION MORE BEARS TO COMENvidia is pulling back, no prominent reason or news article that could have caused this, that leaves the next possible scenarios: - NVDA was rated overvalued by many analysts and is now drawing back - Covid market volatility is causing unpredictable movements - Upcoming US elections, many worry about the China tension According to the chart we are close to the first possible support. However if that level doesn't hold, next support line is only around $485. Yahoo Finance estimates a -21% pullback as an overvalued stock. That leaves us at roughly 418. eToro estimates a low of $400. However, the long term outlook is still positive. Monitor these 4 indicators to look out for a trend reversal and buy the dip as low as you can. Hit like if you found this helpful. Thanks, Ev
NASDAQ:NVDA
by BlockTechEv
Is Zoom Losing its Zip?If any company represents the unprecedented social, economic and technological disruptions of the coronavirus pandemic, it would have to be Zoom Video Communications. The teleconferencing stock not only joined the Nasdaq-100 in April. It’s also the index’s top gainer in 2020, up about 600 percent. Its market cap of $138 billion ranks it ahead of venerable names like Qualcomm , Union Pacific and Chevron . But that’s also resulted in valuations that dwarf most other companies. ZM’s triple-digit price-to-sales and price-to-earnings ratios exceed most other widely traded stocks. (Aside from a few biotechs.) This may create the risk of profit taking or rotation into other corners of the market. ZM’s price action could already be showing signs of fatigue. First, the weekly chart. Last week was both an inside week and a spinning-top candle stick. Both are potential reversal patterns. Next, the daily chart shows a descending trendline since September 23. While patterns like this can be bullish (like Nvidia ), it’s a little concerning with a stock so far above any clear support lines. Third, ZM has been losing relative strength as the market’s bounced. It’s mostly flat since the September 24 low, while the S&P 500 and Nasdaq-100 have advanced more than 5 percent. Finally, MACD has crossed lower and is now falling. In conclusion, ZM might not fall right away. But it could be losing its shine. Tech investors may see it as a source of funds and shift toward chips and Chinese tech stocks , which continue to gain relative strength. TradeStation is a pioneer in the trading industry, providing access to stocks, options, futures and cryptocurrencies. See our Overview for more.
NASDAQ:ZM
by TradeStation
4
$PFE Expect A Move Towards $41.94Technical Analysis Currently, $PFE is respecting an Ascending Triangle chart pattern, where buyers are unable to break the resistance level of $39.00, but has been making a slope of higher lows. As of 1/10/2020 close, the price is resting at $36.37, near the slope of higher lows. Coincidentally, we are also near the end of Wave 4, as the price is currently around 38.2% of the Wave 3 mark. As such, these support a very strong bullish Wave 5 Ascending Triangle continuation theory. Entries, Price Targets, Stop Losses Based on the 1/10/2020 closing price of $36.37, regardless of whether you are averaging your positions or taking a new position, it is currently at a sweet spot for a new entry. Personally, I have also taken a new position at $36.36. I believe that the optimal time for entry is when prices are below $36.46 and at the same time, stays above the slope of higher lows. As for my price target, it is at $41.94, where it lies in a zone of resistance, right between the 5.62 markers and 7.90 markers. Do note that during Wave 3, a price increase of $7.99 was seen, while during Wave 1, a price increase of $11.33 was seen. Since Wave 3 cannot be the shortest of the 3 Impulse Wave, Wave 5 will likely be less than a $7.99 price increase. As long as the price breaks the $39.00 to $39.47 resistance zone towards the upside, I'm positive that the momentum from the breakout will bring the price towards $41.94, minimally reaching the 5.62 markers as established in the chart. I place my initial stop-loss at $33.73, but as the price rise and respect the Ascending Triangle, you should adjust your stop-loss upwards by the same amount as the rise using a trailing stop-loss. This is because while as Ascending Triangle chart pattern usually indicates a bullish breakout, this is not always the case. Sometimes, the resistance zone may be too strong, causing a bearish breakout. As such, a stop-loss below the slope of higher lows should be in place as a precaution. Disclaimer I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor. All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment, or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies. I will not and cannot be held liable for any actions you take as a result of anything you read here. Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise. If this post has helped you out in making your investment/trading decision, give it a huge thumbs up, and follow for more updates regarding this ticker symbol!
NYSE:PFELong
by UnknownUnicorn6361804
1
MRNA HOLD BULLISHI am not swinging this one, even though it is tempting. I recently sold NVAX at 15% profit, and due to strong correlation with MRNA I was considering selling my MRNA as well, in which case I would have made 14% right now. However, I decided to hold because of 2 reasons : 1) AstraZeneca just took a major hit (if you don't know about it, catch up on the news). This takes out a bit of competition and investor fund distribution might come this way 2) MRNA shows a strong uptrend with good momentum, and that is mainly why I will HOLD it for longer term. Hit like if you found this helpful and interesting. Thanks, E
NASDAQ:MRNA
by BlockTechEv
9
MRNA - THE CEO THAT SOLD - SHARE YOUR FEEDBACKPLEASE READ THE ENTIRE POST, IT MIGHT JUST SAVE YOU A SOUR INVESTMENT I have been following MRNA for about a month now, and something interesting has happened that not many people know about. On 4 September, news came out that the CMO, the President AND the CEO have sold large if not all of their holdings.* Now the company says that this is no reason to panic. (sounds like what we were told about corona in December...) On the trading platform I use, I have also gotten a notification about insiders selling. This is a built in strategy used along with others to determine the market consensus of the stock (buy, strong buy, hold etc) We can all probably agree that when head management sell most of their holdings, and not 1 person but 3 senior members, it is generally not a good sign. Now here is where I'd like your feedback - The large selling off their stocks hasn't been reflecting in the market. In fact, MRNA has been on one long bull run with minor short term bearish chart patterns. Why would it be that the sell off doesn't reflect in the market? I personally sold my stock immediately after I saw a report on this from Gurufinder, later confirmed by more mainstream news and other platforms. My opinion is that The company has to portray that they believe their stocks are going all the way up which in this case, selling off massive holdings at the peak tells me that they are taking their profit. Compare this to PFE (Pfizer), whos director INCREASED his holdings. Now that speaks of confidence in the company, right? * INFO FROM MY TRADING PLATFORM CEO, SOLD $1,293,810, DATE 18.09.20 PRESIDENT, SOLD $1,228,468, DATE 15.09.20 CMO, SOLD $1,255,321, DATE 15.09.20 Please share your constructive and respectful feedback, and thank you ! Hit like if you found this interesting, Ev
NASDAQ:MRNA
by BlockTechEv
7
NVAX UP 13%NVAX is HOT right now. Earlier yesterday I expected a pullback, but there is no way of telling when the buy craze will end. What I'm monitoring from the chart: Momentum, to indicate a possible trend reversal - for now the momentum is still HOT RSI, also to monitor momentum and buy power - right now the buyers are in firm control Bollinger Bands, to monitor the volatility and overbought / oversold area - we have been running overbought for days So at this point, NVAX is going incredibly strong but I am keeping an eye out for a possible sell off or minor correction to enter again with a lower position. Hit like if you found this helpful Thanks, E
NASDAQ:NVAX
by BlockTechEv
1
$VBIV 10 Day MA Reversal and Curl on the Daily10 day MA reversal and curl. Today's candle is just now passing though the 10 day MA but still presents an opportunity for the bears so if the bulls keep the price up we may be able to break this and that should give confirmation of a bullish reversal. Inverted hammer appearing after the series of red candles is indicative that a reversal is about to occur. However, since the next candle did not open above the previous day's close, this indicates the bears may still take control. Further confirmation would be needed to take the trade long.Depending on risk tolerance 2.84-3.02 stop/loss 4.56 target, if it blows past that... woo hoo!
V
by VelvetBarbie
1
RVV.C — FDA Phase 3 Clinical Trials Approval for COVID-19 DrugRevive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19 TORONTO, July 31, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food & Drug Administration (“U.S. FDA”) has approved the Company to proceed with a randomized, double-blind, placebo-controlled confirmatory Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. “The FDA approval of the Phase 3 study to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19 is a tremendous milestone for Revive and I am very proud of the dedication of our team and partners to bring forward a potential new treatment option for patients with a confirmed diagnosis of COVID-19 globally,” said Michael Frank, Revive’s Chief Executive Officer. “We thank the FDA for recognizing the importance of this Phase 3 study and we are now focused on executing on our plans for initiating the clinical trial in an expeditious manner.” About the Phase 3 Confirmatory Clinical Study The Phase 3 confirmatory clinical study titled, “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19”, will enroll up to 1,000 patients that will be randomized 1:1:1 to receive Bucillamine 100 mg three times a day (“TID”), Bucillamine 200 mg TID or placebo TID for up to 14 days. The primary objective is to compare frequency of hospitalization or death in patients with mild-moderate COVID-19 receiving Bucillamine therapy with those receiving placebo. The primary endpoint is the proportion of patients meeting a composite endpoint of hospitalization or death from the time of first dose through Day 28 following randomization. Efficacy will be assessed by comparison of clinical outcome (death or hospitalization), disease severity using the 8-category NIAID COVID ordinal scale, supplemental oxygen use, and progression of COVID‑19 between patients receiving standard-of-care plus Bucillamine (high dose and/or low dose) and patients receiving standard-of-care plus placebo. Safety will be assessed by reported pre-treatment adverse events and treatment-emergent adverse events (including serious adverse events and adverse events of special interest), laboratory values (hematology and serum chemistry), vital signs (heart rate, respiratory rate, and temperature), and peripheral oxygen saturation. An interim analysis will be performed by an Independent Data and Safety Monitoring Board (“DSMB”) after 210 patients have been treated and followed up for a total of 28 days after randomization. The better performing Bucillamine dose at the interim analysis will be selected and patients will then be randomized 2:1 to the selected Bucillamine dose or placebo. Additional interim analyses will be performed after 400, 600, and 800 patients have reached this same post-treatment timepoint. The independent DSMB will actively monitor interim data for the ongoing safety of patients and will recommend continuation, stopping or changes to the conduct of the study based on the interim analysis reports. Scientific Rationale of Bucillamine for COVID-19 Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to increase antioxidant activity of cellular glutathione2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via increasing glutathione activity and other anti-inflammatory activity, to lessen the destructive consequences of SARS-CoV2 infection in the lungs and attenuate the clinical course of COVID-19. The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.
CSE:RVVLong
by wealth_bakery
VST.C -- Gearing up for Wave 2 up move on COVID-19 newsVST has its hand in a number of sectors, including a sizeable holding in FANS (esports/gambling stock) but it has recently gained attention because of its stake in the rapid COVID-19 test manufacturer. Yesterday, they've announced that they are increasing their manufacturing capacity by 5M test kits per month. In the followup webinar, investors were informed of several pending orders with large corporate and government bodies. The company is under NDA at the moment but there will be followup news releases as the orders are fulfilled. Their COVID-19 test has received authorization in a number of major jurisdictions, including most recently Brazil which faces one of the worst COVID-19 outbreaks at the moment. The company reported record numbers in most recent financials, nearly doubling its net income ($4.7M) from the same 6 month period of last year. Technically, yesterday marked a decisive reversal after ~50% retrace from recent high and it appears the chart is gearing up for Wave 2 move that should see re-test (and likely break) through resistance around 1.10. ---------------------------------------------------------------- Victory Square Health Increases Monthly Production of Rapid Covid-19 Test Kits to Meet Increased Demand with New Manufacturing Agreement with Gold Analisa Diagnostica Ltda VANCOUVER, British Columbia, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Victory Square Health Inc./Safetest (“VS Health” or the "Company") – portfolio company of Victory Square Technologies Inc. ("Victory Square") (CSE:VST) (OTC:VSQTF) (FWB:6F6) – is pleased to announce entering into a manufacturing contract for their IgG and IgM Rapid Test Kits for the detection of Covid-19 for sales and distribution globally. The latest manufacturing agreement will allow the company to produce an additional 5,000,000 VS Health Covid-19 Rapid Tests monthly for Global distribution. This additional manufacturing contract will also enable the Company to enter into additional global sales agreements in various industries which have shown interest, including retail, hospitality, pharmaceutical, correctional facilities, casino, border services, education, airport, military, government, and more. “Based on our outreach and discussions, the demand for our exclusive test from distributors around the world is very high,” said Victory Square Health CEO Felipe Peixoto. “Given that demand, this new capacity-building manufacturing contract is a significant boost to our plan to be a positive solution around the world. To that end, Victory Square Health is committed to providing assistance to as many nations as possible through these distribution channels.” The new Victory Square Health/Safetest manufacturer is Gold Analisa Diagnostica Ltda., a Government-recognized manufacturer of bio products in Brazil and has operated for over 30 years. Gold Analisa is ISO 9001: 2015 certified by DNV - DET NORSKE VERITAS in the scope of production, marketing and technical-scientific advisory services for products for in vitro diagnostic use. Gold Analisa has Anvisa's Good Manufacturing and Control Practices certificate with hivital, and also participates in the PNCQ - National Quality Control Program, sponsored by SBAC – Sociedade Brasileira de Análises Clínicas. Gold Analisa has a distribution network that aims to be close to customers, covering the entire national territory of Brazil. “We’re completely energized by this critical new manufacturing contract which will allow Victory Square Health to fulfill the tremendous demand for its exclusive Rapid Test kits on a global scale,” said Shafin Diamond Tejani, CEO of Victory Square Technologies, of which Victory Square Health is a portfolio company. “We are actively working together on other production partnership agreements to further increase our production capacity.”
CSE:VSTLong
by wealth_bakery
Etsy Has Deepest Pullback Since its Rally BeganE-commerce has grown dramatically in the era of coronavirus, as most traders know. A lot of the attention has obviously focused on the big names like Amazon.com, but smaller player Etsy has risen even more. ETSY crushed forecasts the last time it reported on August 5, with revenue more than doubling from the previous year. The stock ran into the news and then drifted lower. It’s now approaching some interesting levels. First, ETSY’s low today of $116.63 is slightly above its early-July peak. Second, it’s barely $1 above the 50-day simple moving average. That’s the closest it’s gotten to the 50-day SMA since early April. The shares are also oversold based on stochastics. Given the short-term weakness, traders may wait a little longer before doing much with ETSY. There could also be opportunities nearer $110 if there’s one final push to the downside. Still, ETSY’s been a very strong name in an important corner of the market. It may be time to start watching it around these levels.
NASDAQ:ETSY
by TradeStation
KNR.C -- Breakout on lab validation of COVID-19 detection techUndervalued and overlooked company, in my opinion with the a successful energy efficiency and management line of products with partners like Toyota, Beyond Meat, Brookfield and others. Cash flow positive. $41M mkt cap and 31M float with 45% insider ownership. Only getting noticed now, after introducing Biocloud virus detection tech that is undergoing testing for real-time detection of COVID-19 in enclosed spaces. Today marked an important first step - lab validation - but there's more to come. Next week, we should expect the news of testing using COVID-19. Lots of hype, certainly, but the fundamental strength of this business is undeniable. Kontrol’s COVID-19 Technology Prototype Receives Positive Lab Test Results TORONTO, ON / ACCESSWIRE / August 27, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) ("Kontrol" or "Company") is pleased to announce that the Kontrol BioCloud (or "BioCloud") fully functioning prototype was able to operate in real-time and has received positive lab test results. "Following lab testing, we have demonstrated that our fully operating prototype, previously announced on August 10, 2020, can detect COVID-19 specific components in air samples under a controlled experiment," says Paul Ghezzi, Chief Executive Officer of Kontrol. "This was a critical milestone that we achieved as it ensures the safety and operating capability of BioCloud and we can now move quickly to testing against the live aerosolized COVID-19 virus. We remain on track with achieving our specific milestones and anticipate live COVID-19 virus testing during the week of August 31." The controlled testing was conducted by the lab of independent consultant, Dr. David Heinrichs, PhD (Heinrichs Laboratory) - experts in the study of Microbiology and Immunology. Next Major Milestones The company has now tested both its proprietary detection chamber as announced on August 19, 2020 and its fully operating prototype. Following testing with the live COVID-19 virus, the Company anticipates that it will be in a position to move to commercialization and production of operating units shortly thereafter. We continue to fund all BioCloud technology development through internal cash generation and Kontrol will not raise capital to complete testing and pre-commercialization work. When testing against the live COVID-19 virus the Company seeks to establish the lower detection limits of BioCloud and set final parameters for applications based on room size and number of individuals. These lower detection limits will be part of commercialization specifications. Commercialization Plans "We are excited to have a working prototype and a successful result given all the hard work that has gone into the BioCloud," says Gary Saunders VP of Kontrol. "We have sourced all the components required for commercialization and have our supply chain ready to go. The Canadian Government has recently announced $2 billion in federal funding to help schools reopen safely. BioCloud has the potential to be an important tool in creating safe spaces by seeking to detect for the virus and assessing the effectiveness of HVAC system improvements by continuously sampling air in real-time." The Company anticipates a selling price in the range of $12,000 US per BioCloud unit based on the current supply chain components. The detection chamber is replaceable and represents a potential secondary source of commercialized revenue for Kontrol. Any time the detection chamber comes into contact with the COVID virus it must be disposed of safely and replaced. New Applications beyond COVID-19 During testing the Company has determined that BioCloud has the capability to detect other airborne viruses in addition to COVID-19. This determination was made based on working with the independent lab consultants and a review of the detection mechanism and specifications. While COVID-19 is the most pressing concern for creating safe spaces, other airborne viruses may have similar characteristics that BioCloud may be able to detect. About Kontrol BioCloud BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others. It can be an important technology which supports the entire system of individual testing and contact tracing. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. About Kontrol Energy Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions. Kontrol Energy is one of Canada's fastest growing companies in 2018 and 2019 as ranked by Canadian Business and Maclean's.
K
by wealth_bakery
1